Melbourne medical manufacturer Telix Pharmaceuticals has partnered with a major Japanese engineering company to market its TLX-250 imaging program for cancer patients.
JFE Engineering is an expert of cyclotron infrastructure and radiopharmaceutical manufacturing, and has received clinical interest around the prospect for domestic production of new medical isotopes.
Telix develops diagnostic and therapeutic products for molecularly-targeted radiation (MTR), addressing medical needs for renal, prostate and brain cancers.
“Japan generally represents potentially the second-largest market for our imaging products after the United States,” said Telix CEO Christian Behrenbruch.
“This agreement with JFE paves the way to making our products available to Japanese cancer patients.
“JFE’s tremendous experience and operational capability is a real asset to our commercial plans in Japan.”
The exclusive agreement will focus initially on technology transfer and a feasibility assessment for producing the TLX-250 for the Japanese market.
Both companies will work together to conduct initial pilot studies at several key Japanese nuclear medicine centres.
They will also liaise with the Pharmaceuticals and Medical Devices Agency (PMDA) to extend Telix’s operational activity beyond Europe and the US.
“We are very pleased to be working in partnership with Telix to develop a manufacturing and market-access strategy for Japan,” said Shigeki Yamazaki, JFE’s medical director.
“The unique geographical and regulatory requirements of the Japanese radiopharmaceutical industry means that centralised manufacturing of novel radiopharmaceutical products is a significant commercial opportunity that can deliver important benefits to patients.”